Dual GIP/GLP-1 receptor agonist with superior weight reduction outcomes vs semaglutide alone.
A small-molecule GLP-1 receptor agonist. Unlike peptide GLP-1 analogues it is not a peptide and does not require injection or the absorption enhancers used by oral semaglutide, which is why it is studied as a once-daily oral option.
Active ingredient in Mounjaro and Zepbound. SURMOUNT-1 trial showed ~22% average body weight loss — significantly higher than semaglutide's ~15%.
The GIP component may contribute to improved tolerability, with some researchers reporting fewer GI side effects than pure GLP-1 agonists. GIP receptors are also expressed in bone and may have additional metabolic effects.